The dual role of empagliflozin: Cardio renal protection in T2DM patients

被引：3
作者：
Shafiq, Aimen [1 ]
Mahboob, Eman [1 ]
Samad, Muhammad Ammar [1 ]
Rehman, Mohammad Hassam Ur [1 ]
Tharwani, Zoaib Habib [1 ]
机构：
[1] Dow Univ Hlth Sci, Dow Med Coll, Fac Med, Karachi, Pakistan
来源：
ANNALS OF MEDICINE AND SURGERY | 2022年 / 81卷
关键词：
Empagliflozin; Type 2 diabetes mellitus; Cardio protective; Reno protective; Side effects; COTRANSPORTER; 2; INHIBITOR; TYPE-2; DIABETES-MELLITUS; ESTABLISHED CARDIOVASCULAR-DISEASE; BETA-CELL DYSFUNCTION; DOUBLE-BLIND; SGLT2; INHIBITORS; ADD-ON; KIDNEY-DISEASE; OUTCOMES; RISK;
D O I：
10.1016/j.amsu.2022.104555
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Empagliflozin (Jardiance (R)) is an insulin independent antihyperglycemic agent used in treatment of T2D.The drug is a sodium glucose cotransporter-2 (SGLT2) inhibitor approved in USA and Europe and other countries of the world. As empagliflozin demonstrates cardioprotective and Reno protective properties its prime target are patients having CVD and CKD complicated by T2D. This review sheds light on mechanism of action of the drug and with the help of clinical outcomes establishes the use of empagliflozin in T2D patients.Although empagliflozin is a well-tolerated and easy to administer drug, it has some side effects and contraindications which are discussed in the article to help the reader weigh its beneficial effects against its adverse effect and understand its use in clinical medicine.
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Assessment of the Safety, Efficacy, and Benefit of Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Heart Failure With Reduced Ejection Fraction (HFrEF) at High Risk for Cardiovascular Events
    Towiargi, Ruba
    Fetyani, Lama
    Aljahdali, Naila
    Alnofeie, Adnan
    Alnoamy, Yahya
    Ghandorah, Reham
    Abduljawad, Abrar
    Alharbi, Njood
    Alghanmi, Alanoud
    AlButi, Hala
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (12)
  • [22] SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction A Paradigm Shift Toward Dual Cardio-Renal Protection
    Rastogi, Tripti
    Girerd, Nicolas
    HEART FAILURE CLINICS, 2022, 18 (04) : 561 - 577
  • [23] The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis
    Scholtes, Rosalie A.
    van Raalte, Daniel H.
    Correa-Rotter, Ricardo
    Toto, Robert D.
    Heerspink, Hiddo J. L.
    Cain, Valerie
    Sjostrom, C. David
    Sartipy, Peter
    Stefansson, Bergur, V
    DIABETES OBESITY & METABOLISM, 2020, 22 (04) : 549 - 556
  • [24] Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis
    Tian, Qi
    Guo, Keyu
    Deng, Jiayi
    Zhong, Yanjun
    Yang, Lin
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (02) : 540 - 547
  • [25] Depressive Symptoms and Metabolic Dysregulation Control: A Closer Look at Control Challenges in T2DM Patients
    Yang, Yang
    Xing, Zhenhua
    DEPRESSION AND ANXIETY, 2024, 2024
  • [26] An update on current type 2 diabetes mellitus (T2DM) druggable targets and drugs targeting them
    Uniyal, Prerna
    Panwar, Surbhi
    Bhatt, Akanksha
    Marianesan, Arockia Babu
    Kumar, Roshan
    Singh, Thakur Gurjeet
    Tyagi, Yogita
    Bushi, Ganesh
    Gaidhane, Abhay M.
    Kumar, Bhupinder
    MOLECULAR DIVERSITY, 2025,
  • [27] Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
    Margonato, Davide
    Galati, Giuseppe
    Mazzetti, Simone
    Cannistraci, Rosa
    Perseghin, Gianluca
    Margonato, Alberto
    Mortara, Andrea
    HEART FAILURE REVIEWS, 2021, 26 (02) : 337 - 345
  • [28] COPD and T2DM: a Mendelian randomization study
    Wang, Tao
    Li, Jinshuai
    Huang, Chun
    Wu, Xiangjian
    Fu, Xiaoyan
    Yang, Chunfeng
    Li, Minfang
    Chen, Sheng
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [29] Examining the Links Between Physical Activity, Sitting Time, and Renal Function in T2DM Patients
    Wang, Xiaoyu
    Yan, Ning
    Pan, Ruiping
    Dang, Yuqi
    Wang, Liqun
    DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 : 2469 - 2476
  • [30] RENAL EFFECTS AND NEPHROPROTECTION INDUCED BY THE SGLT2 INHIBITOR EMPAGLIFLOZIN IN PATIENTS WITH DIABETES MELLITUS: A LITERATURE REVIEW
    Morales-Buenrostro, Luis E.
    Citlali Juarez-Comboni, Sonia
    Aldrete Velasco, Jorge
    Rodriguez Alcocer, Alma Nelly
    REVISTA DE NEFROLOGIA DIALISIS Y TRASPLANTE, 2017, 37 (01): : 48 - 61
12345